Ab cellera stock bot
AbCellera Biologics is strategically evolving from a technology--enabled drug discovery partner into an integrated biotech company, focusing on advancing its internal programs through mid-- to late--stage development. The company anticipates a Phase II data readout for ABCL635, a non--hormonal treatment for vasomotor symptoms, by the end of the third quarter of 2026.